GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed…
Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia),…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
Industry Leaders Join Ingenio Cares Mission to Redefine Access, Coordination, and Value in U.S. Healthcare
OAK BROOK, Ill., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Ingenio Care, Inc.,…
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),…
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
October 17, 2025 16:05 ET Â | Source: Jade Biosciences Presentations to highlight…
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App
India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to…
